A Phase 2 interventional study of ABT-089 and ABT-089 in Alzheimer's Disease, sponsored by Abbott. Terminated at 42 sites in United States. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2011-08-23.
Sponsored by Abbott · Phase 2, Interventional, and Treatment
The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for Alzheimer's disease.
3,678 studies on the registry are indexed under Alzheimer Disease; 872 are open to participants now.
This study's enrollment of 337 is above the median of 70 across 2,808 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Abbott is the lead sponsor of 350 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: ABT-089
Drug: ABT-089
Drug: ABT-089
Drug: ABT-089
Drug: ABT-089
Drug: ABT-089
Drug: placebo
10 mg - capsules once daily for 12 weeks
5 mg - capsules once daily for 12 weeks
15 mg - capsules once daily for 12 weeks
20 mg - capsules once daily for 12 weeks
30 mg - capsules once daily for 12 weeks
35 mg - capsules once daily for 12 weeks
placebo - capsules once daily for 12 weeks
Safety and Tolerability
Time frame: Baseline to Final Evaluation
Pharmacokinetics (how the body handles the study drug)
Time frame: Baseline to Final Evaluation
Pharmacodynamic (how the study drug affects cognitive functions such as thinking and memory)
Time frame: Baseline to Final Evaluation
This study is terminated, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abbott